Highly aggressive pancreatic cancer may be potentially treated with Trop2 TAA incorporated into the envelope of SIV VLPs, although co-administration with gemcitabine may be required for optimal protection (Cubas et al., 2011). Here, TACSTD2 is linked to pancreatic neoplasm.